What is the recommended management for a 59-year-old woman with a femoral‑neck T‑score of –2.7 and a recent fragility fracture?

Immediate Pharmacologic Treatment Required

This 59-year-old woman with a femoral neck T-score of –2.7 and a fragility fracture requires immediate initiation of oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) combined with calcium 1,200 mg daily and vitamin D 800 IU daily. 1

Why Treatment is Mandatory

The presence of a fragility fracture alone mandates pharmacologic therapy, regardless of bone density or FRAX score. 1 This patient meets the highest-risk criterion because:

• Any history of fragility fracture triggers immediate treatment, even with osteopenia (T-score > –2.5), as this represents severe osteoporosis by clinical definition 1
• Her femoral neck T-score of –2.7 places her in the osteoporosis range (T-score ≤ –2.5), further confirming the need for aggressive intervention 2, 1
• Post-fracture patients have a 1.5- to 9.5-fold increased risk of subsequent fractures, making this a critical therapeutic window 3

First-Line Pharmacologic Regimen

Oral bisphosphonates are the mandatory first-line therapy based on high-certainty evidence showing approximately 50% reduction in hip fractures and 47–56% reduction in vertebral fractures. 1

Specific Dosing Options:

• Alendronate 70 mg once weekly (preferred) 1, 4
• Risedronate 35 mg once weekly (alternative) 1
• Zoledronic acid 5 mg IV annually (if oral formulations cannot be tolerated) 1

Critical Administration Instructions:

• Take oral bisphosphonates on an empty stomach, 0.5–2 hours before food or other medications 1
• Separate from calcium supplements—calcium inactivates bisphosphonates 1
• Remain upright for 30 minutes after oral bisphosphonate administration 4

Essential Supplementation (Non-Negotiable)

All patients must receive calcium 1,200 mg daily and vitamin D 800 IU daily, as pharmacologic therapy is significantly less effective without adequate supplementation. 1

• Target serum 25-hydroxyvitamin D ≥ 20 ng/mL 1
• If documented vitamin D deficiency (< 20 ng/mL), prescribe high-dose repletion: vitamin D₂ 50,000 IU weekly for 8–12 weeks, then monthly maintenance 1

Mandatory Lifestyle Modifications

Implement the following evidence-based interventions concurrently: 1

• Weight-bearing aerobic exercise (walking, jogging) ≥ 30 minutes on ≥ 3 days per week
• Resistance and muscle-strengthening exercises to reduce fall risk
• Balance-training programs to prevent falls
• Smoking cessation (tobacco accelerates bone loss)
• Limit alcohol to ≤ 1–2 standard drinks per day
• Maintain healthy body weight (BMI < 19 kg/m² is an independent fracture risk factor)

Evaluation for Secondary Causes

Perform comprehensive workup for secondary contributors to bone loss: 1

Laboratory screening should include:

• Serum calcium, phosphorus, alkaline phosphatase
• 25-hydroxyvitamin D level
• Parathyroid hormone (PTH)
• Thyroid function tests 5
• Consider serum testosterone/SHBG/LH/FSH if hypogonadism suspected 5

Key secondary causes to assess: 1

• Vitamin D deficiency
• Hypogonadism/premature menopause (age < 45 years)
• Glucocorticoid exposure (≥ 5 mg prednisone daily for ≥ 3 months)
• Malabsorption disorders
• Hyperparathyroidism, hyperthyroidism
• Chronic alcohol or opioid misuse

Treatment Duration and Monitoring

• Initial bisphosphonate therapy: 5 years 1
• Do NOT monitor bone density during the initial 5-year treatment period—bisphosphonates reduce fractures even when BMD does not increase 1
• After 5 years, reassess fracture risk using FRAX to determine if continued therapy is warranted 1

Second-Line Option (If Bisphosphonates Cannot Be Used)

Denosumab 60 mg subcutaneously every 6 months is indicated for: 1

• Patients with contraindications or intolerance to bisphosphonates
• Severe renal impairment (eGFR < 35 mL/min)

Critical warning: Never discontinue denosumab abruptly without transitioning to bisphosphonate therapy—abrupt discontinuation causes multiple vertebral fractures in some patients. 1

Common Pitfalls to Avoid

The "osteoporosis care gap" is well-documented: only 1–20% of fragility fracture patients receive appropriate osteoporosis diagnosis and treatment. 6, 7, 3 Do not fall into this trap by:

• Assuming orthopedic fracture care alone is sufficient
• Waiting for "more severe" osteoporosis before treating
• Delaying treatment for additional testing
• Failing to prescribe calcium/vitamin D alongside bisphosphonates

Safety Monitoring

Common adverse effects (not serious): 1

• Mild upper GI symptoms with oral bisphosphonates
• Influenza-like symptoms, myalgias, arthralgias after zoledronic acid infusion

Rare but serious adverse effects: 1

• Osteonecrosis of the jaw
• Atypical subtrochanteric femoral fractures

High-certainty evidence shows no difference in serious adverse events compared to placebo at 3+ years. 1

Agents to Avoid

The American College of Physicians strongly recommends AGAINST: 1

• Menopausal estrogen therapy (increased stroke, VTE, breast cancer risk)
• Estrogen plus progestogen therapy (higher invasive breast cancer and mortality)
• Raloxifene (elevated thromboembolic events, pulmonary embolism, cerebrovascular death)